Share on StockTwits

ACADIA Pharmaceuticals (NASDAQ:ACAD) CEO Uli Hacksell sold 15,000 shares of the stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $22.89, for a total value of $343,350.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

ACADIA Pharmaceuticals (NASDAQ:ACAD) traded down 1.35% on Friday, hitting $22.59. 974,585 shares of the company’s stock traded hands. ACADIA Pharmaceuticals has a 52-week low of $15.64 and a 52-week high of $32.00. The stock’s 50-day moving average is $21.43 and its 200-day moving average is $22.53. The company’s market cap is $2.246 billion.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings data on Tuesday, August 5th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.05. Analysts expect that ACADIA Pharmaceuticals will post $-0.85 EPS for the current fiscal year.

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.